Page 16 - Cipla

Cipla launches Roche's Covid antibody cocktail in India for Rs 60k per dose

The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate Covid-19 in adults and pediatric patients

Cipla, Ubio Biotech launches RT-PCR test kit 'ViraGen' for Covid in India

Drug major Cipla on Thursday announced the commercialisation of its RT-PCR test kit 'ViraGen' for Covid-19 in India, in partnership with Ubio Biotechnology Systems

Cipla dips 4% on lower than expected March quarter earnings

The company's performance in Q4FY21 was weighed by moderate YoY growth in India Domestic Formulation (DF)/South Africa and decline in API sales for the quarter

Stocks to watch: Bharti Airtel, L&T, Cipla, Geojit Financial, Hero MotoCorp

Punjab National Bank (PNB) on Saturday said it has raised Rs 1,800 crore by selling 53 crore shares on a private placement basis to investors like LIC and Societe Generale

Cipla open to forge a partnership to distribute Covid-19 vaccines in India

The company already makes and markets antiviral drugs like remdesivir, favipiravir in India apart from importing and distributing Roche's tocilizumab (Actemra)

Cipla Q4 profit up 73% at Rs 412 cr, total revenue at Rs 4,606 cr

Drug major Cipla on Friday posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20. Total revenue from operations rose to Rs 4,606 crore as compared with Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing. For the entire 2020-21 fiscal year, the drug maker reported a consolidated net profit of Rs 2,389 crore as against Rs 1,500 crore in the previous year. Total revenue from operations for the last fiscal year rose to Rs 19,160 crore as against Rs 17,132 crore in 2019-20. The company's board recommended a final dividend of Rs 5 per share (face value Rs 2 each) for 2020-21. Cipla shares on Friday ended flat at Rs 904.10 apiece on the BSE.

Cipla inks pact with Eli Lilly to produce, sell Covid-19 treatment drug

Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of Covid-19

Spiralling demand, leakages and a flourishing black market for remdesivir

Artificial shortages and brazen hawking of the drug on the streets at 15x the normal price rule the day as the official machinery tries desparately to stamp out the parallel market

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Chhattisgarh may sue Cipla for not meeting remdesivir supply requirements

According to Singh Deo, the Indian pharma major had reneged on the contract signed on April 3 to supply Remdesivir injections to the state

US respiratory portfolio to drive medium term sales growth for Cipla

In the domestic market, growth is expected to come from Covid-related drugs

Covid-19: Jharkhand seeks Centre's nod to import Remdesivir from Bangladesh

Jharkhand government sought permission from the Centre to import 50,000 vials of the Covid-19 drug from a Bangladeshi pharmaceuticals company

Cipla doubles remdesivir production to meet 'unprecedented' demand

Just two months ago, Cipla had projected falling demand for remdesivir in India as coronavirus infections were on a steady decline.

Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs

Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade

Cipla board approves reappointment of Umang Vohra as MD & Global CEO

Pharma major Cipla on Tuesday said its board hasapproved the re-appointment of Umang Vohra as the Managing Director and Global CEO of the company for a further period of five years. The board of directorshas considered and approved the re-appointment ofUmang Vohra, Managing Director, designated as 'Managing Director and Global Chief ExecutiveOfficer' of the company, for a further period of five years w.e.f. April 1, 2021 to March 31,2026, Cipla said in a regulatory filing. Vohra had joined Cipla in 2015 and has been the MD & Global CEO of the company since September 1, 2016, it added. "As Cipla's MD & GCEO, Vohra's priorities have been Cipla's strategic growth, defining and executing Cipla's roadmap to maintain momentum in home markets whilst strengthening its presence in other regions, consolidating its core focus areas, augmenting capability, and building the right organisation," the filing said. After gaining degrees in engineering, marketing and finance, Vohraworked with ..

Cipla liquidates wholly-owned unit as part of internal reorganisation

Drug major Cipla on Saturday said it has voluntarily liquidated a wholly-owned step-down subsidiary.

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla stock went up by almost 3 per cent on Tuesday

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.

Cipla receives USFDA nod for nasal spray for treating migraine attacks

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks

Cipla plans to double share from consumer health business in 5 years

Transitioning brands from prescription and trade generics to over-the-counter